Navigation Links
Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma
Date:6/18/2013

LONDON, June 18, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for orphan oncology and oncology supportive care indications.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168)

Edison has today published a comprehensive report examining the investment merits of BioAlliance Pharma, focusing in particular on the potential of its lead product, Livatag, for hepatocellular carcinoma. Livatag is in a Phase III study, RELIVE, which is expected to render final results in 2016. The report identifies a number of earlier catalysts, including the potential partnering of Sitavig for cold sores, which was approved by the FDA in April 2013. Edison has valued BioAlliance at €109m based on a risk-adjusted net present value model.

For the full report see: http://www.edisoninvestmentresearch.com/research/company/bioalliance-pharma

The launch of coverage on BioAlliance is part of a programme of research initiations on healthcare companies worldwide. Edison provides research coverage on more than 130 healthcare companies in Europe, North America and Australia. Edison has pioneered a scientific, detail-oriented approach to analysing companies in the healthcare sector that is delivered in a concise and non-promotional manner. It aims to inform investors, while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by comprehensive and rigorous financial models. Edison's reports provide an overall company valuation w
'/>"/>

SOURCE Edison Investment Research and BioAlliance Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CellHealth Institute is Named 2013 Edison Award Winner
2. Stanford scientists spark new interest in the century-old Edison battery
3. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
4. Julabo USA Inc. Expands Its Line of Compact and Economic Cooling Circulators
5. Rocky Mountain Biologicals Expands Custom Serum Filtration Facility
6. GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
7. GLM Displays Expands Its Line of Formulate Fabric Displays with the Vibe 10ft Display
8. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
9. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
10. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
11. Abacus International Expands Annual Partnership With HealthEconomics.Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 02, 2015 Sterlitech is proud ... testing system at the 2015 AMTA Membrane Technology Conference ... of a decade’s worth of engineering and customer feedback, ... a wide range of applications across an array of ... to meet the dynamic needs of researchers and engineers ...
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, ... XON ), a leader in synthetic biology, today announced ... Specialty Fruits (OSF), the pioneering agricultural company behind ... first non-browning apple. Through the acquisition, Intrexon expands its ... more appetizing and convenient for consumers while providing economic ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Global Market Report of Trypsin 2014-2018 2
... Switzerland and PARIS, October 13 Debiopharm,Group ... companies,with a focus on the development of ... Ipsen (Euronext: FR0010259150; IPN), an innovation-driven,global specialty ... of Decapeptyl(R)[1] (triptorelin embonate[2],22.5 mg) successfully completed ...
... 12 Epeius Biotechnologies Corporation today announced more stunning ... world,s first and, so far only, tumor-targeted genetic medicine ... therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has ... much-touted biologics have failed to do: that is, to ...
... study presented at the 49th Interscience Conference on Antimicrobial ... UV device to decontaminate hospital rooms at the Cleveland ... its ability to remove troublesome bacteria, including C. difficile ... germicidal energy to decontaminate air and surfaces, including those ...
Cached Biology Technology:Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 2Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 3Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 4Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 5Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 6Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 3Researchers Present 'a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination' 2Researchers Present 'a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination' 3
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... 2009 -- With each passing year, the human population of ... wide ranging strain on our water and soil resources, as ... the issue of food security. One way that scientists are ... seeds, both as a method of improving crop yields as ...
... Gene therapy , Gene therapy is the introduction of genetic ... a therapeutic effect. In recent years, it has been ... or even cure several fatal diseases for which there is ... for hereditary diseases, but also for other diseases that affect ...
... in safe and effective administration of potential antiviral drugs ... first step in development of a new kind of treatment ... 4 as an advance online publication of Nature Materials ... and treatment of human disease," said lead author Kim ...
Cached Biology News:Food security: It starts with seed 2Moving gene therapy forward with mobile DNA 2Nanotechnology holds promise for STD drug delivery 2